Superparamagnetic Bifunctional Bisphosphonates Nanoparticles: A Potential MRI Contrast Agent for Osteoporosis Therapy and Diagnostic
Open Access
- 1 January 2010
- journal article
- Published by Hindawi Limited in Journal of Osteoporosis
- Vol. 2010, 1-7
Abstract
A bone targeting nanosystem is reported here which combined magnetic contrast agent for Magnetic Resonance Imaging (MRI) and a therapeutic agent (bisphosphonates) into one drug delivery system. This new targeting nanoplatform consists of superparamagneticnanoparticles conjugated to 1,5-dihydroxy-1,5,5-tris-phosphono-pentyl-phosphonic acid (di-HMBPs) molecules with a bisphosphonate function at the outer of the nanoparticle surface for bone targeting. The as-synthesized nanoparticles were evaluated as a specific MRI contrast agent by adsorption study onto hydroxyapatite and MRI measurment. The strong adsorption of the bisphosphonates nanoparticles to hydroxyapatite and their use as MRIcontrast agent were demonstrated. Cellular tests performed on human osteosarcoma cells (MG63) show that@di-HMBP hybrid nanomaterial has no citoxity effect in cell viability and may act as a diagnostic and therapeutic system.
Keywords
Funding Information
- Magnisense Company
This publication has 22 references indexed in Scilit:
- Progress in functionalization of magnetic nanoparticles for applications in biomedicineJournal of Physics D: Applied Physics, 2009
- Advances in osteoporosis imagingEuropean Journal of Radiology, 2009
- Superparamagnetic nanovector with anti-cancer properties: γFe2O3@ZoledronateInternational Journal of Pharmaceutics, 2009
- Bis-phosphonates–ultra small superparamagnetic iron oxide nanoparticles: a platform towards diagnosis and therapyChemical Communications, 2008
- Biodistribution, Clearance, and Biocompatibility of Iron Oxide Magnetic Nanoparticles in RatsMolecular Pharmaceutics, 2008
- Superparamagnetic iron oxide particles: contrast media for magnetic resonance imagingApplied Organometallic Chemistry, 2004
- The role of bisphosphonates in oncologyDrugs of the Future, 2004
- Comparative biodistribution of thin‐coated iron oxide nanoparticles TCION: Effect of different bisphosphonate coatingsDrug Development Research, 2001
- Experimental and Clinical Pharmacology: Bisphosphonates - mechanisms of actionAustralian Prescriber, 2000
- Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitroProceedings of the National Academy of Sciences, 1999